Sub-Total: $0.00 USD
Bradykinin Receptors B1R and B2R in Disease Research and Drug Discovery
Bradykinin receptors B1R and B2R are G protein-coupled receptors (GPCRs) that play roles in inflammation, vascular biology, pain signaling, and tissue injury responses. As key components of the kallikrein-kinin system, the Bradykinin receptors translate bradykinin-family peptide activity into cellular responses that influence vascular permeability, smooth muscle tone, immune cell activation, and nociception. Their distinct expression profiles and disease associations make these receptors important targets for drug discovery programs focused on inflammatory disease, pain, angioedema, cardiovascular disorders, and metabolic dysfunction.
Understanding Bradykinin Receptor Biology
B1R and B2R are seven-transmembrane GPCRs activated by kinin peptides, including bradykinin, kallidin, and their des-Arg metabolites. While both receptors participate in inflammatory signaling, they differ substantially in their biology. B2R is constitutively expressed in many tissues and is the primary receptor for bradykinin under normal physiological conditions. It mediates rapid responses such as vasodilation, vascular permeability, smooth muscle contraction, nitric oxide and prostaglandin production, and sensory nerve activation.
B1R, in contrast, is typically expressed at low levels in healthy tissue but is strongly induced by inflammatory cytokines, tissue injury, oxidative stress, and infection. This inducible expression pattern makes B1R especially relevant in chronic or persistent disease states, where receptor upregulation can amplify inflammatory and pain pathways. B1R preferentially responds to des-Arg kinins, which are generated by carboxypeptidase cleavage of bradykinin and kallidin.
Upon activation, the Bradykinin receptor family signals through G proteins, particularly Gq-mediated pathways, leading to phospholipase C activation, intracellular calcium mobilization, protein kinase C activity, MAPK signaling, and downstream transcriptional responses. These pathways support physiological repair and host defense, but when dysregulated, they can contribute to pathological inflammation, edema, hyperalgesia, and tissue remodeling.
Bradykinin Receptors in Disease
B2R is best known for its role in hereditary angioedema (HAE), a disorder in which mutations in the SERPING1 gene reduce the amount of C1 esterase inhibitor (C1-INH) in the blood. Without this protein, the coagulation factor enzyme becomes unregulated, leading to increased Bradykinin levels and recurrent episodes of swelling in the skin, gastrointestinal tract, and airway.
Beyond angioedema, B2R signaling contributes to vasodilation, blood pressure regulation, vascular permeability, renal function, and inflammatory pain. These functions make B2R both therapeutically attractive and biologically complex. Blocking B2R may be beneficial in diseases driven by excessive vascular leakage or bradykinin-mediated pain, but drug discovery programs must carefully consider the receptor’s role in normal cardiovascular and renal homeostasis.
B1R has emerged as a target of interest in chronic inflammation, neuropathic pain, diabetes-related complications, and neuroinflammatory disease. Preclinical studies have linked B1R activation to inflammatory hyperalgesia, leukocyte recruitment, endothelial activation, and cytokine-driven tissue damage, supporting continued interest in B1R antagonists for chronic disease settings.
Bradykinin Receptors in Drug Discovery
For drug discovery researchers, the Bradykinin receptors present both opportunity and challenge. As GPCRs, they are highly druggable targets, amenable to small-molecule, peptide, and biologic-based approaches. However, their biology is context-dependent, ligand-specific, and influenced by disease state, tissue environment, and inflammatory tone.
B2R drug discovery has benefited from the clinical validation of receptor antagonism in HAE. Icatibant, a selective B2R antagonist, is approved for the treatment of acute HAE attacks in adults, demonstrating that direct pharmacological modulation of bradykinin receptor signaling can produce meaningful clinical benefit. Ongoing research continues to explore how B2R modulation may apply to other disorders involving edema, pain, inflammatory signaling, and vascular dysfunction.
B1R discovery efforts are often focused on antagonist development for diseases where the receptor is pathologically induced. However, translating B1R biology into successful therapeutics requires assays that capture receptor activation under relevant cellular conditions, including cytokine-primed or disease-mimicking environments.
Screening Against Bradykinin Receptors
Comprehensive screening of Bradykinin receptor activity provides valuable insight into compound function, potency, and receptor selectivity. For agonist or pathway-bias studies, reporter-based systems can help researchers evaluate downstream transcriptional responses and compare activity across receptor contexts. For antagonist programs, functional assays can determine whether a compound blocks ligand-induced signaling at the intended receptor without interfering with the other bradykinin receptor subtype.
This receptor-pair screening strategy is particularly useful for programs focused on inflammation and pain, where each Bradykinin receptor subtype may contribute to disease biology in different phases. B2R may drive acute bradykinin responses, while B1R may become more prominent during sustained inflammation or tissue injury. Understanding these dynamics can support better translational biomarker development, target selection, and lead optimization.
Advancing Bradykinin Receptor Research
For researchers studying bradykinin receptor signaling, INDIGO’s functional cell-based assays can help characterize compound activity in agonist or antagonist mode. These assays help researchers evaluate potency, efficacy, receptor selectivity, and support lead optimization. By screening across the Bradykinin receptor family, drug discovery teams can gain a clearer understanding of how candidate molecules regulate Bradykinin biology and accelerate the development of targeted therapies for inflammatory, vascular, and pain-related diseases.
References
Cicardi et al. (2010). Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. The New England Journal of Medicine, 363(6), 532–541. https://doi.org/10.1056/NEJMoa0906393
Lau et al. (2020). A Systematic Review of Molecular Imaging Agents Targeting Bradykinin B1 and B2 Receptors. Pharmaceuticals, 13(8), 199. https://doi.org/10.3390/ph13080199
Shen, J. K., & Zhang, H. T. (2023). Function and structure of bradykinin receptor 2 for drug discovery. Acta Pharmacologica Sinica, 44(3), 489–498. https://doi.org/10.1038/s41401-022-00982-8